Balancing novelty with confined chemical space in modern drug discovery

Bibliography

• Bohanec S, Zupan J. Structure generation of constitutional isomers from structural fragments. J Chem Inf Comput Sci 1991;31(4):531-40
   Google Scholar
• Pearlman RS, Smith KM. Novel software tools for chemical diversity. Perspect Drug Discov Des 1998;9-11:339-53
   Google Scholar
• Virshup AM, Contreras-García J, Wipf P, et al. Stochastic voyages into uncharted chemical space produce a representative library of all possible drug-like compounds. J Am Chem Soc 2013;135(19):7296-303
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Martínez-Mayorga K, Giulianotti MA, et al. Visualization of the chemical space in drug discovery. Curr Comput Aided Drug Des 2008;4(4):322-33
   Web of Science ®Google Scholar
• Fitzgerald SH, Sabat M, Geysen HM. Diversity space and its application to library selection and design. J Chem Inf Model 2006;46(4):1588-97
   PubMed Web of Science ®Google Scholar
• Ruddigkeit L, Blum LC, Reymond J-L. Visualization and virtual screening of the chemical universe database gdb-17. J Chem Inf Model 2013;53(1):56-65
   PubMed Web of Science ®Google Scholar
• Barbosa AJM, Del Rio A. Freely accessible databases of commercial compounds for high- throughput virtual screenings. Curr Top Med Chem 2012;12(8):866-77
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL. Chemoinformatic characterization of the chemical space and molecular diversity of compound libraries. In: Andrea T, editor, Diversity-oriented synthesis: basics and applications in organic synthesis, drug discovery, and chemical biology. John Wiley & Sons, Inc., Hoboken, NJ; 2013. p. 325-52
   Google Scholar
• Ganesan A. The impact of natural products upon modern drug discovery. Curr Opin Chem Biol 2008;12(3):306-17
   PubMed Web of Science ®Google Scholar
• López-Vallejo F, Nefzi A, Bender A, et al. Increased diversity of libraries from libraries: chemoinformatic analysis of bis-diazacyclic libraries. Chem Biol Drug Des 2011;77(5):328-42
   PubMed Web of Science ®Google Scholar
• Houghten RA, Pinilla C, Giulianotti MA, et al. Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing, in vivo, and enhanced deconvolution by computational methods. J Comb Chem 2008;10(1):3-19
   PubMed Web of Science ®Google Scholar
• Rognan D. Towards the next generation of computational chemogenomics tools. Mol Inf 2013; In press; doi:10.1002/minf.201300054
   Web of Science ®Google Scholar
• Deng Z-L, Du C-X, Li X, et al. Exploring the biologically relevant chemical space for drug discovery. J Chem Inf Model 2013;53(11):2820-8
   PubMed Web of Science ®Google Scholar
• Paolini GV, Shapland RHB, van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol 2006;24(7):805-15
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4(11):682-90
   PubMed Web of Science ®Google Scholar
• Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10(7):507-19
   PubMed Web of Science ®Google Scholar
• Nisius B, Bajorath J. Mapping of pharmacological space. Expert Opin Drug Discov 2011;6(1):1-7
   PubMed Web of Science ®Google Scholar
• Clemons PA, Bodycombe NE, Carrinski HA, et al. Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles. Proc Natl Acad Sci USA 2010;107(44):18787-92
   PubMed Web of Science ®Google Scholar
• Yongye AB, Medina-Franco JL. Data mining of protein-binding profiling data identifies structural modifications that distinguish selective and promiscuous compounds. J Chem Inf Model 2012;52:2454-61
   PubMed Web of Science ®Google Scholar
• Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25(2):197-206
   PubMed Web of Science ®Google Scholar
• Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012;486(7403):361-7
   PubMed Web of Science ®Google Scholar
• Barker A, Kettle JG, Nowak T, et al. Expanding medicinal chemistry space. Drug Discov Today 2013;18(5-6):298-304
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Aguayo-Ortiz R. Progress in the visualization and mining of chemical and target spaces. Mol Inf 2013; In press; doi:10.1002/minf.201300041
   Web of Science ®Google Scholar
• Bajorath J. A perspective on computational chemogenomics. Mol Inf 2013; In press; doi:10.1002/minf.201300034
   Web of Science ®Google Scholar
• Aubé J. Drug repurposing and the medicinal chemist. ACS Med Chem Lett 2012;3(6):442-4
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3(8):673-83
   PubMed Web of Science ®Google Scholar
• Kraft R, Kahn A, Medina-Franco JL, et al. A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions. Dis Model Mech 2013;6(1):217-35
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Garcia-Lopez P, Herrera LA, et al. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 2008;7:82
   PubMed Web of Science ®Google Scholar
• Ma D-L, Chan DS-H, Leung C-H. Drug repositioning by structure-based virtual screening. Chem Soc Rev 2013;42(5):2130-41
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Giulianotti MA, Welmaker GS, et al. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today 2013;18(9-10):495-501
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Martínez-Mayorga K, Peppard TL, et al. Chemoinformatic analysis of GRAS (generally recognized as safe) flavor chemicals and natural products. PLoS One 2012;7(11):e50798
   PubMedGoogle Scholar
• Martinez-Mayorga K, Peppard TL, López-Vallejo F, et al. Systematic mining of generally recognized as safe (GRAS) flavor chemicals for bioactive compounds. J Agric Food Chem 2013;61(31):7507-14
   PubMed Web of Science ®Google Scholar
• Martínez-Mayorga K, Medina-Franco JL, Organizers. Foodinformatics: applications of chemical information to food chemistry. Division of chemical information. 245th ACS National Meeting, New Orleans, LI, United States; American Chemical Society, Washington, DC, New Orleans, LI, United States; 2013
   Google Scholar
• Dooley C, Giulianotti M, McLaughlin J, et al. The direct in vivo screening of mixtures: fast- tracking drug discovery. Biopolymers 2009;92(4):298
   Web of Science ®Google Scholar
• Carroll FI, Houghten RA. From rapid in vitro screening to rapid in vivo screening in the drug discovery process. Neuropsychopharmacology 2009;34(1):251-2
   PubMed Web of Science ®Google Scholar
• Merino A, Bronowska AK, Jackson DB, et al. Drug profiling: knowing where it hits. Drug Discov Today 2010;15(17-18):749-56
   PubMed Web of Science ®Google Scholar
• Clemons PA. Complex phenotypic assays in high-throughput screening. Curr Opin Chem Biol 2004;8(3):334-8
   PubMed Web of Science ®Google Scholar
• Gilbert IH, Leroy D, Frearson JA. Finding new hits in neglected disease projects: target or phenotypic based screening? Curr Top Med Chem 2011;11(10):1284-91
   PubMed Web of Science ®Google Scholar
• Lu Q, Quinn AM, Patel MP, et al. Perspectives on the discovery of small-molecule modulators for epigenetic processes. J Biomol Screening 2012;17(5):555-71
   PubMed Web of Science ®Google Scholar
• Laggner C, Kokel D, Setola V, et al. Chemical informatics and target identification in a zebrafish phenotypic screen. Nat Chem Biol 2012;8(2):144-6
   Web of Science ®Google Scholar
• Scior T, Bender A, Tresadern G, et al. Recognizing pitfalls in virtual screening: a critical review. J Chem Inf Model 2012;52(4):867-81
   PubMed Web of Science ®Google Scholar
• Muegge I. Synergies of virtual screening approaches. Mini Rev Med Chem 2008;8(9):927-33
   PubMed Web of Science ®Google Scholar
• Clark DE. What has virtual screening ever done for drug discovery? Expert Opin Drug Discov 2008;3(8):841-51
   PubMed Web of Science ®Google Scholar
• Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery: a critical review. Curr Med Chem 2013;20(23):2839-60
   PubMed Web of Science ®Google Scholar
• Shultz MD. Setting expectations in molecular optimizations: strengths and limitations of commonly used composite parameters. Bioorg Med Chem Lett 2013;23(21):5980-91
   PubMed Web of Science ®Google Scholar
• Yusof I, Segall MD. Considering the impact drug-like properties have on the chance of success. Drug Discov Today 2013;18(13–14):659-66
   PubMed Web of Science ®Google Scholar
• Muthas D, Boyer S, Hasselgren C. A critical assessment of modeling safety-related drug attrition. MedChemComm 2013;4(7):1058-65
   Web of Science ®Google Scholar
• Hann MM, Keserü GM. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov 2012;11(5):355-65
   PubMed Web of Science ®Google Scholar
• Moroy G, Martiny VY, Vayer P, et al. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov Today 2012;17(1–2):44-55
   PubMed Web of Science ®Google Scholar
• Yongye AB, Medina-Franco JL. Systematic characterization of structure–activity relationships and ADMET compliance: a case study. Drug Discov Today 2013;18(15–16):732-9
   PubMed Web of Science ®Google Scholar
• Dahlgren MK, Garcia AB, Hare AA, et al. Virtual screening and optimization yield low-nanomolar inhibitors of the tautomerase activity of plasmodium falciparum macrophage migration inhibitory factor. J Med Chem 2012;55(22):10148-59
   PubMed Web of Science ®Google Scholar
• Ritchie TJ, Ertl P, Lewis R. The graphical representation of ADME-related molecule properties for medicinal chemists. Drug Discov Today 2011;16(1–2):65-72
   PubMed Web of Science ®Google Scholar
• Dandapani S, Marcaurelle LA. Accessing new chemical space for 'undruggable' targets. Nat Chem Biol 2010;6(12):861-3
   PubMed Web of Science ®Google Scholar
• Faller B, Ottaviani G, Ertl P, et al. Evolution of the physicochemical properties of marketed drugs: can history foretell the future? Drug Discov Today 2011;16(21-22):976-84
   PubMed Web of Science ®Google Scholar
• Roughley SD, Jordan AM. The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. J Med Chem 2011;54(10):3451-79
   PubMed Web of Science ®Google Scholar
• Pitt WR, Parry DM, Perry BG, et al. Heteroaromatic rings of the future. J Med Chem 2009;52(9):2952-63
   PubMed Web of Science ®Google Scholar
• Kennedy JP, Williams L, Bridges TM, et al. Application of combinatorial chemistry science on modern drug discovery. J Comb Chem 2008;10(3):345-54
   PubMed Web of Science ®Google Scholar
• Singh N, Guha R, Giulianotti MA, et al. Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository. J Chem Inf Model 2009;49(4):1010-24
   PubMed Web of Science ®Google Scholar
• Brown N, Jacoby E. On scaffolds and hopping in medicinal chemistry. Mini Rev Med Chem 2006;6(11):1217-29
   PubMed Web of Science ®Google Scholar
• Wetzel S, Klein K, Renner S, et al. Interactive exploration of chemical space with scaffold hunter. Nat Chem Biol 2009;5(8):581-3
   PubMed Web of Science ®Google Scholar
• Schneider G, Neidhart W, Giller T, et al. Scaffold-hopping by topological pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed 1999;38(19):2894-6
   PubMed Web of Science ®Google Scholar
• Evans BE, Rittle KE, Bock MG, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988;31(12):2235-46
   PubMed Web of Science ®Google Scholar
• Lipkus AH, Yuan Q, Lucas KA, et al. Structural diversity of organic chemistry. A scaffold analysis of the CAS registry. J Org Chem 2008;73(12):4443-51
   PubMed Web of Science ®Google Scholar
• Dow M, Fisher M, James T, et al. Towards the systematic exploration of chemical space. Org Biomol Chem 2012;10(1):17-28
   PubMed Web of Science ®Google Scholar
• Ciapetti P, Giethlen B. Molecular variations based on isosteric replacements. In: Wermuth CG, editor, The practice of medicinal chemistry. 3rd edition. Elsevier, Burlington, MA; 2008. p. 290-342
   Google Scholar
• Vogt M, Stumpfe D, Geppert H, et al. Scaffold hopping using two-dimensional fingerprints: true potential, black magic, or a hopeless endeavor? Guidelines for virtual screening. J Med Chem 2010;53(15):5707-15
   PubMed Web of Science ®Google Scholar
• Hartenfeller M, Zettl H, Walter M, et al. Dogs: reaction-driven de novo design of bioactive compounds. PLoS Comput Biol 2012;8(2):e1002380
   PubMed Web of Science ®Google Scholar
• Langdon SR, Brown N, Blagg J. Scaffold diversity of exemplified medicinal chemistry space. J Chem Inf Model 2011;51(9):2174-85
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Martínez-Mayorga K, Bender A, et al. Scaffold diversity analysis of compound data sets using an entropy-based measure. QSAR Comb Sci 2009;28(11-12):1551-60
   Google Scholar
• Yongye AB, Waddell J, Medina-Franco JL. Molecular scaffold analysis of natural products databases in the public domain. Chem Biol Drug Des 2012;80(5):717-24
   PubMed Web of Science ®Google Scholar
• Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 2009;52(21):6752-6
   PubMed Web of Science ®Google Scholar
• Chen CY-C. Tcm database@taiwan: the world's largest traditional Chinese medicine database for drug screening in silico. PLoS One 2011;6(1):e15939
   PubMed Web of Science ®Google Scholar
• López-Vallejo F, Giulianotti MA, Houghten RA, et al. Expanding the medicinally relevant chemical space with compound libraries. Drug Discov Today 2012;17(13–14):718-26
   PubMed Web of Science ®Google Scholar
• Tommasi R, Cornella I. Focused libraries: the evolution in strategy from large-diversity libraries to the focused library approach. In: Bartlett PA, Entzeroth M, editors, Exploiting chemical diversity for drug discovery. The Royal Society of Chemistry; Cambridge, UK; 2006. p. 163-83
   Google Scholar
• Zheng W, Johnson SR. Compound library design - principles and applications. In: Varnek A, Tropsha A, editors, Chemoinformatics approaches to virtual screening. Royal Society of Chemistry; Cambridge, UK: 2008. p. 268-94
   Google Scholar
• Segall MD. Multi-parameter optimization: identifying high quality compounds with a balance of properties. Curr Pharm Des 2012;18(9):1292-310
   PubMed Web of Science ®Google Scholar
• López-Vallejo F, Caulfield T, Martínez-Mayorga K, et al. Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. Comb Chem High Throughput Screen 2011;14(6):475-87
   PubMed Web of Science ®Google Scholar
• Yongye AB, Pinilla C, Medina-Franco JL, et al. Integrating computational and mixture-based screening of combinatorial libraries. J Mol Model 2011;17(6):1473-82
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL. Advances in computational approaches for drug discovery based on natural products. Rev Latinoam Quimioter 2013;41(2):95-110
   Google Scholar
• Ortega A, Blount JF, Manchand PS. Salvinorin, a new trans-neoclerodane diterpene from salvia-divinorum (labiatae). J Chem Soc Perkin Trans 1 1982;10:2505-8
   Google Scholar
• Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 2002;99(18):11934-9
   PubMed Web of Science ®Google Scholar
• Granier S, Kobilka B. A new era of GPCR structural and chemical biology. Nat Chem Biol 2012;8(8):670-3
   PubMed Web of Science ®Google Scholar
• Martinez-Mayorga K, Byler KG, Yongye AB, et al. Ligand/kappa-opioid receptor interactions: insights from the x-ray crystal structure. Eur J Med Chem 2013;66:114-21
   PubMed Web of Science ®Google Scholar
• Yoo J, Medina-Franco JL. Inhibitors of DNA methyltransferases: insights from computational studies. Curr Med Chem 2012;19(21):3475-87
   PubMed Web of Science ®Google Scholar
• Andreoli F, Barbosa AJM, Parenti MD, et al. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des 2013;19(4):578-613
   PubMed Web of Science ®Google Scholar
• Yoo J, Medina-Franco JL. Chemoinformatic approaches for inhibitors of DNA methyltransferases: comprehensive characterization of screening libraries. Comp Mol Biosci 2011;1:7-16
   Google Scholar
• Medina-Franco JL, Edwards BS, Pinilla C, et al. Rapid scanning structure–activity relationships in combinatorial data sets: identification of activity switches. J Chem Inf Model 2013;53(6):1475-85
   PubMed Web of Science ®Google Scholar
• Aguayo-Ortiz R, Pérez-Villanueva J, Hernandez-Campos A, et al. Chemoinformatic characterization of activity and selectivity switches of antiprotozoal compounds. Fut Med Chem 2014; In press; doi:10.4155/FMC.13.173
   PubMed Web of Science ®Google Scholar
• Singh J, Petter RC, Baillie TA, et al. The resurgence of covalent drugs. Nat Rev Drug Discov 2011;10(4):307-17
   PubMed Web of Science ®Google Scholar
• Zinzalla G, Thurston DE. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Fut Med Chem 2009;1(1):65-93
   PubMed Web of Science ®Google Scholar
• Sperandio O, Reynes CH, Camproux AC, et al. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today 2010;15(5-6):220-9
   PubMed Web of Science ®Google Scholar
• Higueruelo AP, Schreyer A, Bickerton GRJ, et al. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des 2009;74(5):457-67
   PubMed Web of Science ®Google Scholar
• Basse MJ, Betzi S, Bourgeas R, et al. 2p2idb: a structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res 2013;41(D1):D824-D7
   PubMed Web of Science ®Google Scholar
• Bienstock RJ. Computational drug design targeting protein-protein interactions. Curr Pharm Des 2012;18(9):1240-54
   PubMed Web of Science ®Google Scholar
• Dhruv H, Loftus JC, Narang P, et al. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis. J Biol Chem 2013; In press; doi:10.1074/jbc.M113.493536
   PubMedGoogle Scholar
• Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today 2013;18(17–18):807-17
   PubMed Web of Science ®Google Scholar
• Bellavista E, Andreoli F, Parenti MD, et al. Immunoproteasome in cancer and neuropathologies: a new therapeutic target? Curr Pharm Des 2013;19(4):702-18
   PubMed Web of Science ®Google Scholar
• Verdine GL, Hilinski GJ. Chapter one - stapled peptides for intracellular drug targets. In: Wittrup KD, Gregory LV, editors, Methods in enzymology. Academic Press, San Diego, CA; 2012. p. 3-33
   Google Scholar
• Floris M, Masciocchi J, Fanton M, et al. Swimming into peptidomimetic chemical space using pepMMsMIMIC. Nucleic Acids Res 2011;39:W261-W9
   PubMed Web of Science ®Google Scholar
• Pakkala M, Hekim C, Soininen P, et al. Activity and stability of human kalikrein-2-specific linear and cyclic peptide inhibitors. J Pept Sci 2007;13(5):348-53
   PubMed Web of Science ®Google Scholar
• De Luca S, Saviano M, Della Moglie R, et al. Conformationally constrained cck8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type b receptor. ChemMedChem 2006;1(9):997-1006
   PubMed Web of Science ®Google Scholar
• Yongye AB, Li YM, Giulianotti MA, et al. Modeling of peptides containing d-amino acids: implications on cyclization. J Comput Aided Mol Des 2009;23(9):677-89
   PubMed Web of Science ®Google Scholar
• Sako Y, Morimoto J, Murakami H, et al. Ribosomal synthesis of bicyclic peptides via two orthogonal inter-side-chain reactions. J Am Chem Soc 2008;130(23):7232-4
   PubMed Web of Science ®Google Scholar
• Baeriswyl V, Heinis C. Polycyclic peptide therapeutics. ChemMedChem 2013;8(3):377-84
   PubMed Web of Science ®Google Scholar
• Whitby LR, Boger DL. Comprehensive peptidomimetic libraries targeting protein-protein interactions. Acc Chem Res 2012;45(10):1698-709
   PubMed Web of Science ®Google Scholar
• Nefzi A, Ostresh JM, Yu J, et al. Combinatorial chemistry: libraries from libraries, the art of the diversity-oriented transformation of resin-bound peptides and chiral polyamides to low molecular weight acyclic and heterocyclic compounds. J Org Chem 2004;69(11):3603-9
   PubMed Web of Science ®Google Scholar
• Schroeder CI, Craik DJ. Therapeutic potential of conopeptides. Fut Med Chem 2012;4(10):1243-55
   PubMed Web of Science ®Google Scholar
• Banerjee J, Yongye AB, Chang Y-P, et al. Design and synthesis of alpha-conotoxin GID analogues as selective alpha4beta2 nicotinic acetylcholine receptor antagonists. Pept Sci 2013; In press; doi:10.1002/bip.22413
   PubMedGoogle Scholar
• Driggers EM, Hale SP, Lee J, et al. The exploration of macrocycles for drug discovery – an underexploited structural class. Nat Rev Drug Discov 2008;7(7):608-24
   PubMed Web of Science ®Google Scholar
• Giordanetto F, Kihlberg J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J Med Chem 2013; In press; doi:10.1021/jm400887j
   Web of Science ®Google Scholar
• Mallinson J, Collins I. Macrocycles in new drug discovery. Fut Med Chem 2012;4(11):1409-38
   PubMed Web of Science ®Google Scholar
• Gasser G, Metzler-Nolte N. The potential of organometallic complexes in medicinal chemistry. Curr Opin Chem Biol 2012;16(1-2):84-91
   PubMed Web of Science ®Google Scholar
• Meggers E. Exploring biologically relevant chemical space with metal complexes. Curr Opin Chem Biol 2007;11(3):287-92
   PubMed Web of Science ®Google Scholar
• García-Ramos JC, Galindo-Murillo R, Cortés-Guzmán F, et al. Metal-based drug-DNA interactions. J Mex Chem Soc 2013;57(3):245-59
   Web of Science ®Google Scholar
• Galan MC, Benito-Alifonso D, Watt GM. Carbohydrate chemistry in drug discovery. Org Biomol Chem 2011;9(10):3598-610
   PubMed Web of Science ®Google Scholar
• Cipolla L, Peri F. Carbohydrate-based bioactive compounds for medicinal chemistry applications. Mini Rev Med Chem 2011;11(1):39-54
   PubMed Web of Science ®Google Scholar
• Horne G, Wilson FX, Tinsley J, et al. Iminosugars past, present and future: medicines for tomorrow. Drug Discov Today 2011;16(3–4):107-18
   PubMed Web of Science ®Google Scholar
• Dembitsky VM. Anticancer activity of natural and synthetic acetylenic lipids. Lipids 2006;41(10):883-924
   PubMed Web of Science ®Google Scholar